Trial-Results center  
Clinical trial results database Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

heart failure - antithrombotics - all type of patients


Related trials

RE-NOVATE 2, 2010 - dabigatran 220mg vs enoxaparin

ADVANCE 2 (CV185-047), 2010 - apixaban vs enoxaparin

WATCH (warfarin vs aspirin), 2009 - warfarin vs aspirin

RECORD 4, 2009 - rivaroxaban vs enoxaparin

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin

RECORD 2, 2008 - extended rivaroxaban vs enoxaparin

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin

ADVANCE-1, 2008 - apixaban vs enoxaparin

RECORD 1, 2008 - extended rivaroxaban vs extended enoxaparin

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin

HELAS (warfarin vs aspirin), 2006 - warfarin vs aspirin

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin

HELAS (warfarin vs placebo), 2006 - warfarin vs placebo

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin

BISTRO II (225mg bid), 2005 - dabigatran 450mg vs enoxaparin

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose

WASH (aspirin), 2004 - aspirin vs no treatment

WASH (warfarin), 2004 - warfarin vs no treatment

PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose

AFASAK II (warfarin low dose vs warfarin standard dose), 1998 - warfarin low dose vs warfarin standard dose



See also:

  • All heart failure clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of warfarin
    		•  

    HELAS (warfarin vs aspirin) study, 2006

    Facebook    pdf : warfarin - antithrombotics for heart failure

    Treatments

    Studied treatment warfarin
    Control treatment aspirin 325mg/d

    Patients

    Patients HF related to ischemic heart disease with LVFE<35%
    Baseline characteristics
    Age (years) 61.6y 
    female (%) 89.3% 
    LVEF (mean), % 29.0% 
    ACE Inhibitors/ARB 56.9% 
    Diuretics 56.2% 
    Digitalis 37.7% 
    B-blockers 15.1% 

    Method and design

    Randomized effectives 54 / 61 (studied vs. control)
    Design Parallel groups
    Blinding Double blind
    Follow-up duration 21.9 months
    Lost to follow-up ND
    Number of centre 40
    Geographic area Europe
    Primary endpoint stroke, PE, ME, hospitalisation, death
    Withdrawals (T1/T0) ND /


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    exacerbation of heart failure

    2 / 54
         3 / 61
         classic 0,75 [0,13;4,34]

    All cause death

    11 / 54
         9 / 61
         classic 1,38 [0,62;3,08]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    exacerbation of heart failure 2 / 54 (3,7%) 3 / 61 (4,9%) 0,75 [0,13;4,34]    
    All cause death 11 / 54 (20,4%) 9 / 61 (14,8%) 1,38 [0,62;3,08]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    exacerbation of heart failure 3,70% 4,92% -12,1‰
    All cause death 20,37% 14,75% 5,6%

    Meta-analysis of all similar trials:

    antithrombotics in heart failure for all type of patients



    Reference(s)

    Trials register # NA
    • Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.. Eur J Heart Fail 2006 Jun;8:428-32
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend